Biogen eyes Regenxbio delivery tech for candidate occular gene therapies

By Gareth Macdonald

- Last updated on GMT

iStock/ktsimage
iStock/ktsimage

Related tags License Initial public offering

Biogen has licensed rights use a gene therapy delivery technology from developer Regenxbio.

The technology consists of a library of 100 novel adeno associated viral vectors (AAV) developed by Regenxbio for gene therapy delivery applications.

Under the license, financial terms of which were not made public, Biogen can select vectors for two rare genetic vision disease therapies it is developing.

Once Biogen has chosen the research license will convert to a commercial agreement under which Regenxbio will receive development milestones and sales royalties if the products are approved.

Regenxbio CEO Kenneth T. Mills said: “This license agreement provides new validation of the potential of our NAV Technology Platform in ocular indications and is an important step in advancing NAV-based gene therapies to people suffering from rare genetic vision disorders.”

This was echoed by Olivier Danos, Biogen’s senior vice president of cell and gene therapy, who said the technology “will enable us to expand our pipeline of treatments with the potential to improve health outcomes in diseases of the eye​.”

Tech licensing

Biogen is the first new technology licensee Maryland-based Regenxbio has announced since completing its initial public offering (IPO) on the NASDAQ Global Select Market in September.

To date the NAV Technology Platform has been used in conjunction with 28 candidate gene therapies, 23 of which are being developed by companies that licensed access to the technology before Regenxbio went public.

The most advanced of these projects are being run by AveXis Inc and Dimension Therapeutics, which each started early-phase trials of gene therapies in January.

Chinese contract services firm Wuxi Apptec is working with Regenxbio to develop scalable production methods for NAV-based gene therapies under a strategic manufacturing deal signed in June.

The firms are currently making Regenxbio’s candidate wet age-related macular degeneration (AMD) therapy RGX-111 for planned Phase I/II trials.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers